Baumal Caroline's most recent trade in Apellis Pharmaceuticals Inc was a trade of 82,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Caroline Baumal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 82,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Caroline Baumal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 39,594 | 93,301 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Caroline Baumal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 1,853 | 53,707 (0%) | 0% | 30.0 | 55,513 | Common Stock |
| Apellis Pharmaceuticals Inc | Caroline Baumal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.81 per share. | 06 Jan 2025 | 2,816 | 55,560 (0%) | 0% | 33.8 | 95,215 | Common Stock |
| Apellis Pharmaceuticals Inc | Caroline Baumal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Baumal Caroline | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 25,445 | 58,376 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Baumal Caroline | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.05 per share. | 04 Jan 2024 | 2,751 | 32,931 (0%) | 0% | 60.1 | 165,207 | Common Stock |
| Apellis Pharmaceuticals Inc | Caroline Baumal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 49,000 | 49,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Caroline Baumal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 35,549 | 35,682 (0%) | 0% | 0 | Common Stock |